サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1411369

抗虚血剤市場：タイプ、適応症、投与経路、エンドユーザー別- 世界予測2024-2030年

Anti-Ischemic Agents Market by Type (Antiplatelet Agents, Calcium Channel Blockers, Organic Nitrates), Indication (Angina Pectoris, Ischemic Stroke, Myocardial Infarction), Route of Administration, End-User - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 184 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.53円
抗虚血剤市場：タイプ、適応症、投与経路、エンドユーザー別- 世界予測2024-2030年
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗虚血剤市場規模は2023年に3億5,588万米ドルと推定され、2024年には3億7,899万米ドルに達し、CAGR 6.23%で2030年には5億4,343万米ドルに達すると予測されます。

抗虚血剤の世界市場

主な市場の統計
基準年[2023］ 3億5,588万米ドル
予測年[2024] 3億7,899万米ドル
予測年 [2030] 5億4,343万米ドル
CAGR（%） 6.23%
抗虚血剤 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは抗虚血剤市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、抗虚血剤市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-抗虚血剤市場の市場規模および予測は？

2-抗虚血剤市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-抗虚血剤市場における技術動向と規制の枠組みは？

4-抗虚血剤市場における主要ベンダーの市場シェアは？

5-抗虚血剤市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • ライフスタイルの変化と虚血性疾患の有病率の増加
      • 虚血状態に対する高度な診断ツールと技術の利用の増加
      • 新しい抗虚血剤を開発するための調査活動の急増
    • 抑制要因
      • 高額な治療費
    • 機会
      • 継続的なイノベーションと医薬品開発活動への投資
      • 臨床試験におけるさまざまな利害関係者の連携
    • 課題
      • 関連する副作用と安全性への懸念
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 抗虚血剤市場：タイプ別

  • 抗血小板剤
  • カルシウムチャネルブロッカー
  • 有機硝酸塩
  • カリウムチャネルオープナー
  • ホイブロッカー

第7章 抗虚血剤市場適応症別

  • 狭心症
  • 虚血性脳卒中
  • 心筋梗塞
  • 末梢動脈疾患

第8章 抗虚血剤市場：投与経路別

  • 静脈内投与（IV）
  • オーラル
  • 経皮

第9章 抗虚血剤市場：エンドユーザー別

  • 外来診療
  • ホームケア
  • 病院

第10章 南北アメリカの抗虚血剤市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の抗虚血剤市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの抗虚血剤市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第14章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Alembic Pharmaceuticals Limited
    • AstraZeneca
    • Baxter, Inc.
    • Bayer AG
    • Boehringer Ingelheim
    • Bristol Myers Squibb
    • Cipla Ltd.
    • Dr Reddy's Laboratories Ltd.
    • Eli Lily & Company
    • Eris Lifesciences Ltd.
    • FDC Ltd.
    • Glenmark Pharmaceuticals Ltd.
    • Intas Pharmaceuticals Ltd.
    • Ipca Laboratories Ltd.
    • J B Chemicals and Pharmaceuticals Ltd.
    • Lupin Ltd.
    • Macleods Pharmaceuticals Pvt Ltd.
    • Medley Pharmaceuticals Ltd.
    • Micro Labs Ltd.
    • Natco Pharma Ltd.
    • Novartis AG
    • Pfizer, Inc.
    • Torrent Pharmaceuticals Ltd.
    • Troikaa Pharmaceuticals Ltd.
    • Zydus Lifesciences Ltd.
  • 主要な製品ポートフォリオ

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTI-ISCHEMIC AGENTS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-ISCHEMIC AGENTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTI-ISCHEMIC AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTI-ISCHEMIC AGENTS MARKET DYNAMICS
  • FIGURE 7. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ANTI-ISCHEMIC AGENTS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. ANTI-ISCHEMIC AGENTS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTI-ISCHEMIC AGENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTI-ISCHEMIC AGENTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORGANIC NITRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY POTASSIUM CHANNEL OPENERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY B-BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ANGINA PECTORIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY PERIPHERAL ARTERY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTI-ISCHEMIC AGENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ANTI-ISCHEMIC AGENTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. ANTI-ISCHEMIC AGENTS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 193. ANTI-ISCHEMIC AGENTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. ANTI-ISCHEMIC AGENTS MARKET LICENSE & PRICING
目次
Product Code: MRR-8E22B619331D

[184 Pages Report] The Anti-Ischemic Agents Market size was estimated at USD 355.88 million in 2023 and expected to reach USD 378.99 million in 2024, at a CAGR 6.23% to reach USD 543.43 million by 2030.

Global Anti-Ischemic Agents Market

KEY MARKET STATISTICS
Base Year [2023] USD 355.88 million
Estimated Year [2024] USD 378.99 million
Forecast Year [2030] USD 543.43 million
CAGR (%) 6.23%
Anti-Ischemic Agents Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anti-Ischemic Agents Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-Ischemic Agents Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anti-Ischemic Agents Market, highlighting leading vendors and their innovative profiles. These include Alembic Pharmaceuticals Limited, AstraZeneca, Baxter, Inc., Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Cipla Ltd., Dr Reddy's Laboratories Ltd., Eli Lily & Company, Eris Lifesciences Ltd., FDC Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Ipca Laboratories Ltd., J B Chemicals and Pharmaceuticals Ltd., Lupin Ltd., Macleods Pharmaceuticals Pvt Ltd., Medley Pharmaceuticals Ltd., Micro Labs Ltd., Natco Pharma Ltd., Novartis AG, Pfizer, Inc., Torrent Pharmaceuticals Ltd., Troikaa Pharmaceuticals Ltd., and Zydus Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Anti-Ischemic Agents Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Antiplatelet Agents
    • Calcium Channel Blockers
    • Organic Nitrates
    • Potassium Channel Openers
    • β-Blockers
  • Indication
    • Angina Pectoris
    • Ischemic Stroke
    • Myocardial Infarction
    • Peripheral Artery Diseases
  • Route of Administration
    • Intravenous (IV)
    • Oral
    • Transdermal
  • End-User
    • Ambulatory Care
    • Homecare
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Anti-Ischemic Agents Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-Ischemic Agents Market?

3. What are the technology trends and regulatory frameworks in the Anti-Ischemic Agents Market?

4. What is the market share of the leading vendors in the Anti-Ischemic Agents Market?

5. Which modes and strategic moves are suitable for entering the Anti-Ischemic Agents Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Anti-Ischemic Agents Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Changing lifestyles and rising prevalence of ischemic conditions
      • 5.1.1.2. Increasing utilization of advanced diagnostic tools and techniques for ischemic conditions
      • 5.1.1.3. Surge in research activities for developing new anti-ischemic agents
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing innovations and investment in drug development activities
      • 5.1.3.2. Collaborative efforts among various stakeholders for clinical trials
    • 5.1.4. Challenges
      • 5.1.4.1. Associated side-effects and safety concerns
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Anti-Ischemic Agents Market, by Type

  • 6.1. Introduction
  • 6.2. Antiplatelet Agents
  • 6.3. Calcium Channel Blockers
  • 6.4. Organic Nitrates
  • 6.5. Potassium Channel Openers
  • 6.6. β-Blockers

7. Anti-Ischemic Agents Market, by Indication

  • 7.1. Introduction
  • 7.2. Angina Pectoris
  • 7.3. Ischemic Stroke
  • 7.4. Myocardial Infarction
  • 7.5. Peripheral Artery Diseases

8. Anti-Ischemic Agents Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous (IV)
  • 8.3. Oral
  • 8.4. Transdermal

9. Anti-Ischemic Agents Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Care
  • 9.3. Homecare
  • 9.4. Hospitals

10. Americas Anti-Ischemic Agents Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Anti-Ischemic Agents Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Anti-Ischemic Agents Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. Alembic Pharmaceuticals Limited
    • 14.1.2. AstraZeneca
    • 14.1.3. Baxter, Inc.
    • 14.1.4. Bayer AG
    • 14.1.5. Boehringer Ingelheim
    • 14.1.6. Bristol Myers Squibb
    • 14.1.7. Cipla Ltd.
    • 14.1.8. Dr Reddy's Laboratories Ltd.
    • 14.1.9. Eli Lily & Company
    • 14.1.10. Eris Lifesciences Ltd.
    • 14.1.11. FDC Ltd.
    • 14.1.12. Glenmark Pharmaceuticals Ltd.
    • 14.1.13. Intas Pharmaceuticals Ltd.
    • 14.1.14. Ipca Laboratories Ltd.
    • 14.1.15. J B Chemicals and Pharmaceuticals Ltd.
    • 14.1.16. Lupin Ltd.
    • 14.1.17. Macleods Pharmaceuticals Pvt Ltd.
    • 14.1.18. Medley Pharmaceuticals Ltd.
    • 14.1.19. Micro Labs Ltd.
    • 14.1.20. Natco Pharma Ltd.
    • 14.1.21. Novartis AG
    • 14.1.22. Pfizer, Inc.
    • 14.1.23. Torrent Pharmaceuticals Ltd.
    • 14.1.24. Troikaa Pharmaceuticals Ltd.
    • 14.1.25. Zydus Lifesciences Ltd.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing